Cognition Therapeutics Announces Publication of Complete Results from Phase 1 Clinical Trial of Elayta™

Posted by & filed under News.

— Elayta Crossed Blood Brain Barrier and Reached CNS Levels Associated in Preclinical Studies with Cognitive Improvement — Pittsburgh, Feb. 19, 2019 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on the protection and restoration of synaptic function in neurodegenerative disorders, announced today the publication of clinical data from the Company’s Phase 1… Read more »

Cognition Therapeutics Initiates NIA-Funded SPARC Study of Elayta™ to Assess Changes in Synaptic Density and Cognitive Performance in Alzheimer’s Disease

Posted by & filed under News.

First Longitudinal Study of Novel Synaptic Imaging Agent at Yale Alzheimer’s Disease Research Unit and Yale PET Center PITTSBURGH, June 18, 2018 — Cognition Therapeutics, Inc., a clinical stage neuroscience company focused on synaptic health and restoration in neurocognitive disorders, today announced that patient dosing has begun in the SPARC (Synaptic Protection for Alzheimer’s Restoration… Read more »